Viking Therapeutics' VK2735 Sees Strong Demand Amid Novo Nordisk Launch
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: stocktwits
- Strong Market Demand: Since its U.S. launch in early January, Novo Nordisk's oral Wegovy has seen weekly prescription fills reach 50,000, indicating robust demand for oral GLP-1 therapies, which bodes well for Viking Therapeutics' VK2735 as it positions itself to capture significant market opportunities.
- Clinical Trial Progress: Viking plans to initiate Phase 3 trials for VK2735 in Q3 2026, with encouraging mid-stage data showing patients lost up to 12.2% of their body weight in just 13 weeks, providing strong support for the drug's market potential.
- Solid Financial Position: Viking reported a Q4 2025 loss of $1.38 per share due to increased R&D spending, with full-year expenses rising to $345 million; however, the company ended the year with $706 million in cash and short-term investments, sufficient to fund ongoing trials and data readouts.
- Optimistic Investor Sentiment: On Stocktwits, retail sentiment for VKTX is bullish with extremely high message volume, as investors are optimistic that the upcoming maintenance dosing trial will provide a good opportunity to re-rate the stock price upward, reflecting confidence in the company's future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VKTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VKTX
Wall Street analysts forecast VKTX stock price to rise
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 28.550
Low
70.00
Averages
97.00
High
125.00
Current: 28.550
Low
70.00
Averages
97.00
High
125.00
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Viking Therapeutics Reports 2025 Financial Highlights and Clinical Progress
- Surge in R&D Expenses: Viking's R&D expenses for Q4 2025 reached $153.5 million, a significant increase from $31 million in Q4 2024, primarily driven by rising clinical study costs and salaries, indicating the company's ongoing commitment to drug development despite the resulting substantial net loss.
- Widening Net Loss: The company reported a net loss of $157.7 million for Q4 2025, or $1.38 per share, compared to a net loss of $35.4 million and $0.32 per share in the same quarter of 2024, reflecting high R&D expenditures that may impact short-term financial stability.
- Decline in Cash Reserves: As of December 31, 2025, Viking held $706 million in cash and short-term investments, down from $903 million in 2024, indicating liquidity pressures as the company ramps up R&D spending, necessitating careful future financing strategies.
- Clinical Trial Advancements: The company has completed enrollment for the VK2735 VANQUISH-1 clinical trial and expects to finish enrollment for VANQUISH-2 in Q3 2026, demonstrating significant progress in obesity treatment development, which could lead to product commercialization in the near future.
See More
VIKING THERAPEUTICS STOCK RISES 18.2% FOLLOWING PLANS TO MOVE ORAL OBESITY DRUG INTO LATE-STAGE TRIALS
Viking Therapeutics Stock Surge: Viking Therapeutics shares have increased by 18.2% as the company plans to advance its oral obesity drug into late-stage testing.
Focus on Obesity Treatment: The advancement of the drug indicates a strategic move by Viking Therapeutics to target the growing market for obesity treatments.
See More
Viking Advances Oral VK2735 Obesity Drug into Late-Stage Trials
- Clinical Trial Progress: Viking expects to advance its experimental obesity drug VK2735's oral version into late-stage studies in Q3 2026, while the subcutaneous formulation is currently undergoing late-stage trials, showcasing the company's ongoing innovation in obesity treatment.
- Significant Weight Loss: In a mid-stage trial, patients on VK2735 achieved up to 14.7% mean weight loss over 13 weeks, indicating the drug's potential in weight management, which may attract more patients seeking effective weight loss solutions.
- Financial Performance: Viking reported a Q4 loss per share of $1.38, wider than the $0.91 loss expected by Wall Street analysts, primarily due to increased R&D expenses, although the company ended the quarter with $706 million in cash and short-term investments, demonstrating some financial resilience.
- Positive Market Reaction: On Stocktwits, retail sentiment around VKTX stock remained in the 'bullish' territory, with users expressing optimism about Viking's prospects, reflecting market confidence in its obesity drug development.
See More
Viking Therapeutics' VK2735 Sees Strong Demand Amid Novo Nordisk Launch
- Strong Market Demand: Since its U.S. launch in early January, Novo Nordisk's oral Wegovy has seen weekly prescription fills reach 50,000, indicating robust demand for oral GLP-1 therapies, which bodes well for Viking Therapeutics' VK2735 as it positions itself to capture significant market opportunities.
- Clinical Trial Progress: Viking plans to initiate Phase 3 trials for VK2735 in Q3 2026, with encouraging mid-stage data showing patients lost up to 12.2% of their body weight in just 13 weeks, providing strong support for the drug's market potential.
- Solid Financial Position: Viking reported a Q4 2025 loss of $1.38 per share due to increased R&D spending, with full-year expenses rising to $345 million; however, the company ended the year with $706 million in cash and short-term investments, sufficient to fund ongoing trials and data readouts.
- Optimistic Investor Sentiment: On Stocktwits, retail sentiment for VKTX is bullish with extremely high message volume, as investors are optimistic that the upcoming maintenance dosing trial will provide a good opportunity to re-rate the stock price upward, reflecting confidence in the company's future performance.
See More
U.S. Stocks Plunge as Tech Sector Weighs Down Market
- Tech Sector Retreat: U.S. stocks experienced a significant decline on Thursday, with the S&P 500 down 1.57%, the Dow Jones down 1.34%, and the Nasdaq 100 down 2.04%, primarily driven by a sell-off in the Magnificent Seven tech stocks, indicating concerns over the profitability outlook in the tech sector.
- Cisco Systems Warning: Cisco Systems saw its stock plummet over 12% after forecasting that rising memory chip prices would erode profitability, raising investor concerns about future performance and potentially diminishing market confidence.
- Weak Economic Data: Initial jobless claims in the U.S. fell by 5,000 to 227,000, below the expected 223,000, while January existing home sales dropped 8.4% month-over-month to 3.91 million, marking a 16-month low, which reflects signs of economic slowdown that could impact market sentiment.
- Positive Earnings Season: Despite the overall market downturn, over 76% of S&P 500 companies that reported earnings exceeded expectations, with Q4 earnings projected to grow by 8.4%, indicating strong corporate profitability that may provide support for the market.
See More
US Stock Market Volatility as Tech Stocks Weigh Down Indices
- Tech Stock Pressure: The S&P 500 index fell by 0.52% and the Nasdaq 100 index dropped by 1.08% due to weakness in the Magnificent Seven tech stocks, indicating investor concerns that could dampen market confidence.
- Cisco Profit Warning: Cisco Systems forecasted that rising memory chip prices would erode profitability, leading to a more than 10% drop in its stock price, which may prompt investors to revise down their future performance expectations, negatively impacting overall market sentiment.
- Employment Data Impact: Initial US jobless claims fell by 5,000 to 227,000, reflecting a slightly weaker labor market, which could influence the Federal Reserve's monetary policy decisions and lower market expectations for future rate cuts.
- Chip Demand Recovery: Sandisk's stock rose over 7% following Kioxia's forecast of strong demand for NAND memory chips, indicating growth potential in the AI infrastructure sector, which may create new investment opportunities for related companies.
See More
Viking Therapeutics Reports 2025 Financial Highlights and Clinical Progress
- Surge in R&D Expenses: Viking's R&D expenses for Q4 2025 reached $153.5 million, a significant increase from $31 million in Q4 2024, primarily driven by rising clinical study costs and salaries, indicating the company's ongoing commitment to drug development despite the resulting substantial net loss.
- Widening Net Loss: The company reported a net loss of $157.7 million for Q4 2025, or $1.38 per share, compared to a net loss of $35.4 million and $0.32 per share in the same quarter of 2024, reflecting high R&D expenditures that may impact short-term financial stability.
- Decline in Cash Reserves: As of December 31, 2025, Viking held $706 million in cash and short-term investments, down from $903 million in 2024, indicating liquidity pressures as the company ramps up R&D spending, necessitating careful future financing strategies.
- Clinical Trial Advancements: The company has completed enrollment for the VK2735 VANQUISH-1 clinical trial and expects to finish enrollment for VANQUISH-2 in Q3 2026, demonstrating significant progress in obesity treatment development, which could lead to product commercialization in the near future.
See More
VIKING THERAPEUTICS STOCK RISES 18.2% FOLLOWING PLANS TO MOVE ORAL OBESITY DRUG INTO LATE-STAGE TRIALS
Viking Therapeutics Stock Surge: Viking Therapeutics shares have increased by 18.2% as the company plans to advance its oral obesity drug into late-stage testing.
Focus on Obesity Treatment: The advancement of the drug indicates a strategic move by Viking Therapeutics to target the growing market for obesity treatments.
See More
Viking Advances Oral VK2735 Obesity Drug into Late-Stage Trials
- Clinical Trial Progress: Viking expects to advance its experimental obesity drug VK2735's oral version into late-stage studies in Q3 2026, while the subcutaneous formulation is currently undergoing late-stage trials, showcasing the company's ongoing innovation in obesity treatment.
- Significant Weight Loss: In a mid-stage trial, patients on VK2735 achieved up to 14.7% mean weight loss over 13 weeks, indicating the drug's potential in weight management, which may attract more patients seeking effective weight loss solutions.
- Financial Performance: Viking reported a Q4 loss per share of $1.38, wider than the $0.91 loss expected by Wall Street analysts, primarily due to increased R&D expenses, although the company ended the quarter with $706 million in cash and short-term investments, demonstrating some financial resilience.
- Positive Market Reaction: On Stocktwits, retail sentiment around VKTX stock remained in the 'bullish' territory, with users expressing optimism about Viking's prospects, reflecting market confidence in its obesity drug development.
See More
Viking Therapeutics' VK2735 Sees Strong Demand Amid Novo Nordisk Launch
- Strong Market Demand: Since its U.S. launch in early January, Novo Nordisk's oral Wegovy has seen weekly prescription fills reach 50,000, indicating robust demand for oral GLP-1 therapies, which bodes well for Viking Therapeutics' VK2735 as it positions itself to capture significant market opportunities.
- Clinical Trial Progress: Viking plans to initiate Phase 3 trials for VK2735 in Q3 2026, with encouraging mid-stage data showing patients lost up to 12.2% of their body weight in just 13 weeks, providing strong support for the drug's market potential.
- Solid Financial Position: Viking reported a Q4 2025 loss of $1.38 per share due to increased R&D spending, with full-year expenses rising to $345 million; however, the company ended the year with $706 million in cash and short-term investments, sufficient to fund ongoing trials and data readouts.
- Optimistic Investor Sentiment: On Stocktwits, retail sentiment for VKTX is bullish with extremely high message volume, as investors are optimistic that the upcoming maintenance dosing trial will provide a good opportunity to re-rate the stock price upward, reflecting confidence in the company's future performance.
See More
U.S. Stocks Plunge as Tech Sector Weighs Down Market
- Tech Sector Retreat: U.S. stocks experienced a significant decline on Thursday, with the S&P 500 down 1.57%, the Dow Jones down 1.34%, and the Nasdaq 100 down 2.04%, primarily driven by a sell-off in the Magnificent Seven tech stocks, indicating concerns over the profitability outlook in the tech sector.
- Cisco Systems Warning: Cisco Systems saw its stock plummet over 12% after forecasting that rising memory chip prices would erode profitability, raising investor concerns about future performance and potentially diminishing market confidence.
- Weak Economic Data: Initial jobless claims in the U.S. fell by 5,000 to 227,000, below the expected 223,000, while January existing home sales dropped 8.4% month-over-month to 3.91 million, marking a 16-month low, which reflects signs of economic slowdown that could impact market sentiment.
- Positive Earnings Season: Despite the overall market downturn, over 76% of S&P 500 companies that reported earnings exceeded expectations, with Q4 earnings projected to grow by 8.4%, indicating strong corporate profitability that may provide support for the market.
See More
US Stock Market Volatility as Tech Stocks Weigh Down Indices
- Tech Stock Pressure: The S&P 500 index fell by 0.52% and the Nasdaq 100 index dropped by 1.08% due to weakness in the Magnificent Seven tech stocks, indicating investor concerns that could dampen market confidence.
- Cisco Profit Warning: Cisco Systems forecasted that rising memory chip prices would erode profitability, leading to a more than 10% drop in its stock price, which may prompt investors to revise down their future performance expectations, negatively impacting overall market sentiment.
- Employment Data Impact: Initial US jobless claims fell by 5,000 to 227,000, reflecting a slightly weaker labor market, which could influence the Federal Reserve's monetary policy decisions and lower market expectations for future rate cuts.
- Chip Demand Recovery: Sandisk's stock rose over 7% following Kioxia's forecast of strong demand for NAND memory chips, indicating growth potential in the AI infrastructure sector, which may create new investment opportunities for related companies.
See More
